BlackRock Institutional Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BlackRock Institutional Trust’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.83M	Buy	129,657 +34,548	+36%	+$874K	﹤0.01%	2934
2016 Q3	$2.51M	Buy	95,109 +41,480	+77%	+$823K	﹤0.01%	2966
2016 Q2	$1.06M	Buy	+53,629	New	+$1.04M	﹤0.01%	3288

Other funds holding RETA

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LFWA

LBJ Family Wealth Advisors Austin, Texas $196M AUM 22.12% 1-Year Est. Return

BlackRock Institutional Trust's RETA Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 36% in Q4 2016, buying an estimated $874K and bringing the position to 129,657 shares worth $2.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

BlackRock Institutional Trust first reported a position in RETA in Q2 2016 and has held it in 3 quarters since. 52 funds tracked by Wall St. Rank hold RETA as of Q4 2016.

BlackRock Institutional Trust held 129,657 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $2.83M as of Q4 2016.
BlackRock Institutional Trust bought 34,548 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2016, an estimated $874K.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2934 holding.
BlackRock Institutional Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and has held it in 3 quarters since.
52 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.